SCHEMBL2631146

SCHEMBL2631146

CC[C@@H](C(=O)O)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.39
CHRM1 P11229 2/20 0.36
ADRA1A P35348 2/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HRH1 P35367 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA1 P00915 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12891264 1.00 CA2 (0.41) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL276534 1.00 CA2 (0.41) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL4578586 0.81 CA2 (0.39) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL28651642 0.80 SLC1A3 (0.36) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL9519201 0.79 CA2 (0.38) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL17231916 0.79 CHRM1 (0.50) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL10925798 0.79 CA2 (0.38) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL15821811 0.79 CA2 (0.38) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL1966037 0.79 CHRM1 (0.50) CA2MAPK1TSHRCHRM1ADRA1A
SCHEMBL28678611 0.79 CA2 (0.38) CA2MAPK1TSHRCHRM1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331675-A1 AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) 2023-10-19 US disclosed
WO-2017064628-A1 C-3 NOVEL TRITERPENONE WITH C-28 UREA DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-04-20 WO disclosed
EP-1249731-B1 Photosensitive composition and negative working lithographic printing plate FUJIFILM CORP (JP) 2012-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331675-A1 AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF PDCD1, CD274, PDCD1LG2 CA2 4606/4885MAPK1 353/4885TSHR 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.